
Authorized Representative (AR) and Importer Obligations
The obligation to appoint an authorized representative, the minimum content of the mandate, provisions that cannot be written into it, joint and several liability, termination and uploading it to ÜTS. A Medex ÜTS guide.
The file from your manufacturer abroad has an "EC REP" line, but you hold no signed document between that representative and the manufacturer; in ÜTS an upload box called "Authorisation Document" ("Yetki Belgesi") opens under the "EU Authorised Representative" ("AB Yetkili Temsilcisi") field and you do not know what to put there. Or the only document you have is a distributorship letter the manufacturer gave you, and you are not sure whether it stands in for the authorisation document. These two documents are not the same thing, and the two go to different places in ÜTS.
This page puts the authorised representative and the importer side by side. It sets out, article by article, in which case the manufacturer must appoint a representative, what the authorisation document must contain and what it cannot contain, in which situation the representative is held jointly liable with the manufacturer, the obligations the importer carries in its own right, and by what conduct an importer or a distributor is treated as a manufacturer. The sources are the Medical Device Regulation (Tıbbi Cihaz Yönetmeliği) published in the Official Gazette No. 31499 (bis) of 2/6/2021 and the Manual on Registration Procedures of Medical Devices in the Product Tracking System (Tıbbi Cihazların Ürün Takip Sistemine Kayıt Süreçlerine İlişkin Kılavuz).
Everything written here is drawn from these two texts. If a provision is not in the source, it is not here either.
The obligation to appoint an authorised representative arises only from the place of establishment
The first point of confusion is this: the authorised representative is not an institution tied to the risk or class of the device. Article 11(1) of the Medical Device Regulation says that, where the manufacturer is not established in Turkey or in an EU member state, the device may be placed on the market only on condition that the manufacturer appoints an authorised representative. The criterion is the place of establishment alone.
Article 3(lll) of the same Regulation defines the authorised representative as a natural or legal person established in Turkey or in EU member states who has received a written mandate from a manufacturer established outside Turkey and the EU member states to act on its behalf in relation to specified tasks with regard to its obligations under the Regulation. The phrase "specified tasks" is important; the representative does not take the manufacturer's place.
Article 12(7)(d) of the Manual confirms this on the ÜTS side as well: manufacturers established in an EU member state or in Turkey do not appoint an EU authorised representative, and the obligation exists only for manufacturers not established in an EU member state or in Turkey. For a manufacturer established in Germany you do not need to keep looking for an authorisation document for ÜTS; that manufacturer has no representative and is not expected to have one.
The appointment does not become valid until an authorisation document is issued and accepted in writing
The most common gap in practice is that the representative's name is written on the label and in the declaration of conformity but there is no document behind it. Article 11(2) of the Regulation states that the appointment of an authorised representative becomes valid when a mandate is issued and accepted in writing by the authorised representative. Two conditions are required together: an issued document and the representative's written acceptance.
The same paragraph also sets a floor on scope: the appointment covers, as a minimum, all devices of the same generic device group. Article 3(z) of the Regulation defines a generic device group as a set of devices having the same or similar intended purposes or a commonality of technology allowing them to be classified in a generic manner not reflecting specific characteristics. That is, an authorisation document that covers only one of a manufacturer's three products in the same generic group falls below the minimum scope the Regulation provides for.
Submission of the document to the Agency is a separate obligation. Article 11(3) says that the authorised representative will provide a copy of the authorisation document to the Agency upon request.
The minimum tasks the authorisation document must contain
After saying that the representative will perform the tasks agreed in the authorisation document, Article 11(3) lists the tasks the document must require as a minimum. These are not negotiable; if they are not in the authorisation document, the document is incomplete.
Verification: Point (a) of the same paragraph looks for verification that the EU declaration of conformity and the technical documentation have been drawn up by the manufacturer and, where applicable, that an appropriate conformity assessment procedure has been carried out.
Keeping: Point (b) requires keeping a copy of the technical documentation and the EU declaration of conformity and, where applicable, a copy of the relevant certificate issued under Article 56, including any amendments and supplements, available for submission to the Agency for the period referred to in Article 10(8).
Registration: Point (c) looks for compliance with the registration obligations in Article 31 and verification that the manufacturer has complied with the registration obligations in Articles 27 and 29.
Language: Point (ç) requires that, upon request of the Agency, all the information and documentation necessary to demonstrate the conformity of a device be provided in Turkish and/or in an official EU language that the Agency considers appropriate.
Samples: Point (d) looks for the forwarding to the manufacturer of any request by the Agency for samples or access to a device, and verification that the Agency receives the samples or is given access.
Cooperation: Point (e) requires cooperation with the competent authorities in any corrective or preventive action taken to eliminate or, if that is not possible, mitigate the risks posed by devices.
Complaint forwarding: Point (f) looks for the prompt informing of the manufacturer about complaints and reports from healthcare professionals, patients and users about suspected adverse events relating to a device for which they have been appointed.
Termination: Point (g) requires that the authorisation document be terminated if the manufacturer acts contrary to its obligations under the Regulation.
The same paragraph places a burden on the manufacturer as well: the manufacturer enables the authorised representative to perform these tasks. This is not an abstract sentence; Article 10(8)(c) requires that a manufacturer whose registered place of business is outside Turkey or the EU member states ensure that the documentation necessary for the representative to be able to perform the tasks in Article 11(3) is continuously available.
What cannot be written into the authorisation document
An authorisation document carrying a sentence such as "all obligations of the manufacturer have been transferred" does not make that sentence legally correct. Article 11(4) of the Regulation expressly states that, within the scope of the authorisation document, the manufacturer cannot delegate the obligations set out in paragraphs 1, 2, 3, 4, 6, 7, 9, 10, 11 and 12 of Article 10.
These paragraphs cover, in order: designing and manufacturing the device in accordance with the Regulation, establishing the risk management system, carrying out the clinical evaluation, preparing and keeping the technical documentation up to date, drawing up the EU declaration of conformity and affixing the CE marking, complying with the UDI and registration obligations, establishing and maintaining the quality management system, implementing and keeping up to date the post-market surveillance system, ensuring that the information supplied by the manufacturer accompanies the device, and taking corrective action in case of non-conformity. That is, the technical file, the clinical evaluation, the quality system and post-market surveillance remain with the manufacturer. The representative does not produce these; it verifies that they exist and keeps copies of them.
Joint liability is the real risk the representative carries
Authorised representation is not a mailbox service. Article 11(5) of the Regulation provides that, without prejudice to paragraph 4, where the manufacturer has not complied with the obligations set out in Article 10, the authorised representative will be legally liable for defective devices on the same basis as, and jointly and severally with, the manufacturer.
The practical consequence of this provision is this: the representative must hold its own evidence that the manufacturer has fulfilled its Article 10 obligations. Otherwise the manufacturer's shortcoming falls directly on the representative. The verification task in Article 11(3)(a) and the keeping task in point (b) of the same article are there precisely to manage this risk.
Termination and change of authorised representative
Although termination looks like a one-sided commercial decision, it gives rise to a notification obligation. Article 11(6) says that a representative that terminates the authorisation document on the grounds in Article 11(3)(g) will promptly inform the Agency and, where applicable, the notified body involved in the conformity assessment of the device, of the termination and the reasons for it.
A change of representative is regulated in a separate article. Article 12(1) of the Regulation says that the detailed arrangements for the change will be clearly defined in an agreement between the manufacturer, the incoming authorised representative and, where practicable, the outgoing authorised representative, and requires the agreement to address at least four matters: the date of termination of the outgoing representative's authorisation document and the start date of the incoming representative's authorisation document; the date until which the outgoing representative may be indicated in the information supplied by the manufacturer, including promotional material; the transfer of documents, including confidentiality aspects and proprietary rights; and the obligation of the outgoing representative, after the end of its authorisation document, to forward to the manufacturer or the incoming representative any complaints or reports received by it.
A transfer agreement that does not carry these four headings is incomplete. The last point in particular is often left out: the former representative is obliged to forward complaints that keep arriving even after the document has ended.
Which ÜTS screen the authorisation document is uploaded to
Article 12(7) of the Manual says that, when a firm making a document registration notification and application of the "EU Declaration of Conformity (MDR/IVDR)" ("AB Uygunluk Beyanı (MDR/IVDR)") type registers a declaration belonging to a manufacturer not established in an EU member state or in Turkey, it must declare to the Agency through ÜTS the agreement made between the manufacturer and the EU authorised representative it has appointed and/or the authorisation document drawn up between them. The points of the same paragraph determine how the registration is made.
Point (a) states that, in such document registration notifications, making an entry in the "EU Authorised Representative" field on the ÜTS registration screen is mandatory. Point (b) says that importer firms upload the agreement between the manufacturer and the EU authorised representative and/or the authorisation document to the "Authorisation Document" ("Yetki Belgesi") field that appears under this field; alternatively, a printout of the actor screen of the relevant manufacturer on the EUDAMED website, in which the details of the authorised representative concerned are clearly visible, may be uploaded.
Point (c) states that the original of the document and its sworn-translator Turkish translation are uploaded together to the "Authorisation Document" field, and that no apostille or embassy/consulate certification is required for the original of the authorisation document. Sub-point (1) of the same point says that, if an EUDAMED printout has been uploaded to this field, there is no need to upload a sworn-translator Turkish translation of the printout separately. Point (ç) writes that the document uploaded to the "Authorisation Document" field does not need to be sent physically to the Agency for the assessment of the application.
The detail here is important: no apostille is required for the authorisation document, but the translation must have been made by a sworn translator. If you prefer the EUDAMED actor screen printout, the translation burden disappears.
The verification obligation the importer carries in its own right
The importer is not an extension of the manufacturer; the Regulation gives it an independent checking task. Article 13(1) says that importers will place on the market only devices that comply with this Regulation. Paragraph 2(a) requires the importer, in order to place a device on the market, to verify four things: that the device is CE marked and the EU declaration of conformity has been drawn up; that the manufacturer is identified and that an authorised representative has been appointed by the manufacturer in accordance with Article 11; that the device is labelled in accordance with the Regulation and the required instructions for use accompany the device; and, where required, that a UDI has been assigned by the manufacturer in accordance with Article 27.
Note this: the task of verifying that an authorised representative has been appointed lies not with the manufacturer but with the importer. This is why the party that uploads the authorisation document to ÜTS is the importer.
Point (b) of paragraph 2 of the same article says that an importer who considers, or has reason to believe, that a device is not in conformity with the requirements of the Regulation will not place it on the market until it has been brought into conformity, and will inform the manufacturer and the authorised representative; and that, if the importer considers that the device presents a serious risk or is a falsified device, it will also inform the Agency.
The importer's identification, registration, storage and cooperation obligations
Article 13(3) says that importers will indicate on the device or on its packaging or in a document accompanying the device their name, registered trade name or registered trade mark, the registered place of business at which they can be contacted, and their address; and will ensure that any additional label does not obscure any information on the label supplied by the manufacturer.
Paragraph 4 states that importers will verify that the device has been registered in the electronic system in accordance with Article 29 and will add their own details to the registration in accordance with Article 31. Article 30(2) ties this to a time limit: importers verify, within 2 weeks of placing a device on the market (other than a custom-made device), that the manufacturer or the authorised representative has entered the relevant information in the electronic system; if the information is missing or incorrect, they inform the authorised representative or the manufacturer concerned and add their own details to the entry concerned.
The maintenance of registration data is also tied to time limits. Article 31(4) says that economic operators will update the data in the electronic system within 1 week of any change in the information; paragraph 5 says that the accuracy of the data will be confirmed within 1 year of its submission and every 2 years thereafter, and that, if this is not done within 6 months of the end of these periods, the Agency may take appropriate corrective measures. Paragraph 2 of the same article states that, after verifying the data, the Agency will send the single registration number to the manufacturer, the authorised representative or the importer.
On the storage and cooperation side: Article 13(5) requires ensuring that, while a device is under their responsibility, storage or transport conditions do not jeopardise compliance with the general safety and performance requirements; paragraph 6 requires keeping a register of complaints, non-conforming devices, recalls and withdrawals, and providing the manufacturer, authorised representative and distributors with the information requested for complaint investigations; and paragraph 9 requires keeping a copy of the EU declaration of conformity, and a copy of every certificate issued under Article 56, for the period referred to in Article 10(8). Paragraph 10 provides that, at the request of the Agency, samples of the device are provided free of charge or access is given.
Paragraph 7 says that an importer who considers that a device it has placed on the market is not in conformity with the Regulation will promptly inform the manufacturer and the authorised representative, will cooperate with the manufacturer, the authorised representative and the Agency for corrective action to be carried out, and, if the device presents a significant risk, will promptly inform the Agency and, where applicable, the notified body that issued the certificate, with details of the non-conformity and the corrective action. Paragraph 8 requires that complaints and reports from healthcare professionals, patients or users about suspected adverse events be promptly passed on to the manufacturer and the authorised representative.
In addition, Article 25(1) requires distributors and importers to cooperate with manufacturers or authorised representatives for traceability, and paragraph 2 requires economic operators to be able to identify to the Agency, for the period referred to in Article 10(8), every economic operator to which they have directly supplied the device and every economic operator that has supplied them, and every healthcare institution or healthcare professional to which they have directly supplied the device.
The Authorised Distributorship Certificate and the authorisation document are confused
These two documents are different types in ÜTS and have different functions. Article 23(1) of the Manual defines the "Authorised Distributorship Certificate" ("Yetkili Distribütörlük Belgesi") as a document issued by the manufacturer of the device on behalf of importer firms operating in our country. Paragraph 2 lists the fields that must be in the document and are checked during document review in ÜTS: the name or trade name and address of the manufacturer, the name or trade name and address of the authorised firm, the product scope, the start date and, if any, the end date of the authorisation, and the signature and stamp of the manufacturer's authorised person.
Unlike the authorisation document, this document has a certification requirement. Article 23(4) states that the apostilled version of the document, or the version certified by the embassy/consulate of the Republic of Türkiye in the manufacturer's country, or the original of the document with a verifiable e-Apostille, or the original of the document with a verifiable e-signature, is uploaded in full, with its annexes, to the "Original Document" field. Paragraph 5 says that, where this condition is met, the Turkish translation made by a sworn translator is uploaded to the "Turkish Document" field, and that the translation must carry the translator's name and surname, stamp/signature/seal and a declaration that the translation conforms to the original.
There is also a difference in status. Article 23(9) says that uploading an Authorised Distributorship Certificate to ÜTS is not a mandatory document, so that, even if the record of such a document in ÜTS falls into rejected status for any reason, the device or devices linked to that document remain in registered status. The authorisation document, by contrast, is a mandatory field in the relevant declaration record under Article 12(7)(a). Do not substitute one for the other.
In which situation an importer or distributor is treated as a manufacturer
This is where the most expensive mistake on the importer side arises. Article 16(1) of the Regulation says that a distributor, importer or other natural or legal person assumes the obligations incumbent on manufacturers in three cases:
Making available on the market under its own name: Point (a) covers the person making a device available on the market under its own name, registered trade name or registered trade mark. The point itself contains an exception: it does not apply where a distributor or importer enters into an agreement with the manufacturer under which the manufacturer remains identified as the manufacturer on the label and remains responsible for meeting the requirements placed on manufacturers by the Regulation.
Changing the intended purpose: Point (b) covers changing the intended purpose of a device already placed on the market or put into service.
Modification that may affect conformity: Point (c) covers modifying a device in such a way that compliance with the applicable requirements may be affected.
The last sentence of the same paragraph says that this paragraph does not apply to a person who, without being considered a manufacturer as defined in Article 3(t), assembles or adapts a device already on the market for an individual patient, without changing its intended purpose.
Translation and repackaging are not modification, but they give rise to a 28-day notification
Article 16(2) expressly does not count two activities as modification. Point (a) covers the provision, in respect of a device already placed on the market, of the information supplied by the manufacturer in accordance with point 23 of Annex I, including translation, and of other information necessary to market the device. Point (b) covers changes to the outer packaging, including a change of pack size, if the repackaging is necessary for marketing the device and is carried out in such conditions that the original condition of the device is not affected; for sterile devices, the original condition is presumed to be adversely affected if the packaging that maintains the sterile condition is opened, damaged or adversely affected by the repackaging.
Carrying out these activities does not make you a manufacturer, but it brings three additional burdens. Paragraph 3 says that a distributor or importer carrying out one of these activities will indicate, on the device or, where that is not practicable, on its packaging or in a document accompanying the device, together with the activity carried out, its name, registered trade name or trade mark and registered place of business. Paragraph 4 requires a quality management system containing procedures ensuring that the translation of the information is accurate and up to date, that the activities are carried out in such a way as to maintain the original condition of the device, and that the packaging of the repackaged device is not defective, of poor quality or untidy; this system also covers procedures ensuring that the importer or distributor is informed of any corrective action taken by the manufacturer.
Paragraph 5 sets a clear time limit: a distributor or importer carrying out one of these activities informs the manufacturer and the Agency of its intention at least 28 days before the relabelled or repackaged device is made available on the market, and, upon their request, provides a sample or mock-up of the device, including any translated label and instructions for use. The same paragraph also requires that, within the same 28-day period, a certificate issued by a notified body designated for the types of devices subject to these activities, confirming that the quality management system complies with the requirements in paragraphs 3 and 4, be submitted to the Agency.
Most importers who have Turkish labels printed do not know this last sentence. If you are translating labels, this paragraph concerns you.
The distributor is not the end of the chain but one of its checkpoints
Article 14(2)(a) of the Regulation requires the distributor, before making a device available on the market, to verify that the device is CE marked and that the EU declaration of conformity has been drawn up, that the information supplied by the manufacturer in accordance with Article 10(11) accompanies the device, that, for imported devices, the importer has complied with the requirements of Article 13(3), and, where applicable, that a UDI has been assigned. Point (b) of the same paragraph says that a representative sampling method may be applied for some of these verifications.
The distributor's information chain is also defined. Article 14(4) requires the manufacturer and, where applicable, the authorised representative and the importer to be informed promptly in case of suspected non-conformity; paragraph 5 requires complaints and reports of suspected adverse events to be passed on promptly to the manufacturer and, where applicable, the authorised representative and the importer, and requires a register of complaints, non-conforming devices, recalls and withdrawals to be kept. Paragraph 6 provides that the distributor will give the Agency, upon request, the information and documentation it holds, and that the distributor will be considered to have fulfilled this obligation when the manufacturer or, where applicable, the authorised representative provides the required information.
There is a supply interruption case as well. Article 10/A(3) says that economic operators that receive information from the manufacturer or from another economic operator in the supply chain under paragraph 1 will promptly inform the other economic operators, healthcare institutions and healthcare professionals to which they directly supply the device about the foreseen interruption or discontinuation.
The authorised representative must have its own person responsible for regulatory compliance
A frequently overlooked provision: the legal entity acting as representative also has a person responsible for regulatory compliance. Article 15(6) of the Regulation says that authorised representatives will have permanently and continuously at their disposal at least one person responsible for regulatory compliance who possesses the requisite expertise regarding the regulatory requirements for medical devices, and lists in two points the qualifications by which the requisite expertise is to be demonstrated. This is one of the first questions to ask when assessing an organisation that offers authorised representation.
What we do in the division of roles, and what we cannot do
Within medical device ÜTS registration consultancy, the outputs we produce under this heading are these:
Authorisation document audit: We check the authorisation document you hold line by line against paragraphs 2 and 3 of Article 11, list the missing task points, and write the revision request to be sent to the manufacturer.
Scope check: We compare whether the document covers all devices in the same generic device group with the product list you will register in ÜTS.
ÜTS upload: We fill in the "EU Authorised Representative" and "Authorisation Document" fields according to Article 12(7) of the Manual, and determine whether a sworn translation is needed or whether a printout of the EUDAMED actor screen will be sufficient.
Document distinction: We prepare the Authorised Distributorship Certificate and the authorisation document as separate files, and check whether the certification and translation conditions in paragraphs 4 and 5 of Article 23 are met.
Importer checklist: We tie to a calendar the four verifications in Article 13(2)(a), the 2-week period in Article 30(2) and the update and confirmation obligations in Article 31(4) and (5).
Article 16 risk screen: If you do label translation, repackaging or sales under your own brand, we determine which paragraph of Article 16 you fall under and whether the 28-day notification and the notified body certificate requirement arise.
What we cannot do is clear as well. We cannot produce technical documentation, a clinical evaluation or a quality management system in place of the manufacturer; Article 11(4) already says that these obligations cannot be delegated. We cannot be an authorised representative on your behalf; representation is a separate capacity that gives rise to joint liability under Article 11(5). We cannot assume an authorisation document that the manufacturer has not signed. We give no commitment on when or how the Agency will conclude an application.
Our way of working on the ÜTS side is this: the firm opens a user authorisation for us from its own ÜTS firm page, and we create the document and device records with the "Medical Device Registration Operator" ("Tıbbi Cihaz Kayıt Elemanı") authorisation. Article 39(11) of the Manual says that only users of the firm of the "Medical Device Registration Operator" type can create the application, and paragraph 13 says that an application in "Awaiting Signature" ("İmza Bekliyor") status will be electronically signed by the applicant signatory of the firm. The person who signs the application remains the firm's signatory in every case.
